Latest revenue
$759.9M
as of 2026-03-31
Latest net income
$124.3M
as of 2026-03-31
Net margin
16.4%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Surgical & Medical Instruments & Apparatus (138 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Fair value · DCF
DCF: 10-year forecast of free cash flow, discounted at the company's WACC, with a Gordon-growth terminal at year 10. FCF is proxied by last fiscal-year net income (proper FCF needs CFO − CapEx by year, which we don't store yet). Drag the slider to test your own growth thesis — the dominant assumption in any DCF is what comes next, not what the math does with it. Beta defaults to 1.0 when not reported.
Community sentiment
Where do you think GMED is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $10.86B
- Enterprise value
- $10.30B
- P/E (trailing)
- 20.2×
- Forward P/E
- —
- P/B
- 2.29×
- Dividend yield
- 0.0%
- 52-wk high
- $101.40
- 52-wk low
- $51.79
- Beta
- —
- Shares out
- 135.7M
5-year trend
About GMED
Business description and risk factors will appear here once GMED's latest filing is fully ingested.
Profitability
Gross margin
65.1%
12.4%Operating margin
16.3%
147.8%Net margin
18.3%
347.7%Return on equity
11.8%
377.1%Return on assets
10.1%
417.3%Leverage
Debt / equity
0.16×
38.0%Debt / assets
13.8%
32.8%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $759.9M | +27.0% | $124.3M | +64.7% | 16.4% |
Q4 2025 2025-12-31 | $826.4M | +25.7% | $140.6M | +318.2% | 17.0% |
Q3 2025 2025-09-30 | $769.0M | +22.9% | $119.0M | +129.5% | 15.5% |
Q2 2025 2025-06-30 | $745.3M | +18.4% | $202.8M | +723.1% | 27.2% |
Q1 2025 2025-03-31 | $598.1M | -1.4% | $75.5M | +1160.3% | 12.6% |
Q4 2024 2024-12-31 | $657.3M | — | $33.6M | — | 5.1% |
Q3 2024 2024-09-30 | $625.7M | +63.1% | $51.8M | +5094.0% | 8.3% |
Q2 2024 2024-06-30 | $629.7M | +115.9% | $24.6M | -57.3% | 3.9% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Surgical & Medical Instruments & Apparatus · SIC 3841
Your notes
Keep private notes on GMED — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$11.7M
Net activity
−$11.7M
Distinct insiders
6
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns GMED
Institutional value
$4.82B
Total shares held
58.7M
Distinct holders
415
As of
2026-03-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 10.5M | $904.5M | — | New |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 5.0M | $433.6M | — | New |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.9M | $420.4M | — | New |
| 4 | Invesco Ltd. | 4.3M | $371.9M | — | New |
| 5 | JPMORGAN CHASE & CO | 2.6M | $216.7M | — | New |
| 6 | BANK OF MONTREAL /CAN/ | 2.3M | $198.8M | — | New |
| 7 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 2.0M | $173.2M | — | New |
| 8 | DIMENSIONAL FUND ADVISORS LP | 1.8M | $152.5M | — | New |
| 9 | GENEVA CAPITAL MANAGEMENT LLC | 1.8M | $151.7M | — | New |
| 10 | Boston Trust Walden Corp | 1.3M | $108.1M | — | New |
| 11 | ANTIPODES PARTNERS Ltd | 897.6K | $77.3M | — | New |
| 12 | Artemis Investment Management LLP | 848.5K | $73.1M | — | New |
| 13 | Bank of New York Mellon Corp | 742.6K | $64.0M | — | New |
| 14 | Stephens Investment Management Group LLC | 714.7K | $61.6M | — | New |
| 15 | Global Alpha Capital Management Ltd. | 694.4K | $59.8M | — | New |
| 16 | VANGUARD FIDUCIARY TRUST CO | 692.4K | $59.7M | — | New |
| 17 | ANCHOR CAPITAL ADVISORS LLC | 639.5K | $55.1M | — | New |
| 18 | Capital World Investors | 574.5K | $49.5M | — | New |
| 19 | Swedbank AB | 562.4K | $48.5M | — | New |
| 20 | UBS Group AG | 543.1K | $46.8M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once GMED's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.